THERAPY INNOVATIONSDR. OLAF SCHERMEIER HARRY DE WIT3.3

Safe harbor statement:This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward-looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA’s (FMC AG & Co. KGaA) Annual Report on Form 20-F under the heading “Forward-Looking Statements” and under the headings in that report referred to therein, and in FMC AG & Co. KGaA’s other reports filed with the Securities and Exchange Commission (SEC) and the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in Euro if not mentioned otherwise.

10/8/2020Workshop | Therapy Innovations Page 3

INNOVATION PIPELINE

INTERNALR&D

InnovationPortfolio

INTERNAL PROJECTS AND EXTERNALLY SOURCED OPPORTUNITIES

INTERNAL & EXTERNAL R&D PROJECTSInternal research activities focusing on expanding the renal care continuum portfolio

FME VENTURESStrategic investments in start-ups to get access to new technologies in core- and adjacent businesses as wellas new therapy approaches (xenotransplantation)

UNICYTERegenerative medicine based therapies within the fields of renal care and beyond

NXSTAGE & XENIOSResearch & development activities focusing on critical care technologies & therapies in and for hospitals

DMC

INTERNALR&D

Leverage core competencies for additional medical value creation

▪ Regenerative medicine and xeno-transplantation in renal care and beyond

10/8/2020Workshop | Therapy Innovations Page 4

CONTINUOUSLY EXPANDING OUR PORTFOLIO

WE LEVERAGE OUR DEEP TECHNOLOGY AND THERAPY EXPERTISE WITH A VERTICALLY INTEGRATED, USER CENTRIC, DIGITAL AND AGILE ENVIRONMENT TO REMAIN THE LEADER IN COMPREHENSIVE RENAL CARE

Dialysis Business, Value Based Care models, expansion along the renal patient journey to further enhance patient experience

▪ Data analytics and digital innovationto enable patient centric andindividualized therapies

Extracorporeal blood treatments and respiratory solutions

▪ Xenios and NxStage Critical Care solutions to further expand the critical care portfolio

10/8/2020Workshop | Therapy Innovations Page 5

FOCUS ON NEW AND TRANSFORMATIVEFIBER TECHNOLOGY

POTENTIAL FOR BREAKTHROUGH CHANGE IN DIALYZER TECHNOLOGY

OPTIFLUX ENEXA RECEIVED BREAKTHROUGH STATUS FROM FDA & IS A 510(K) REGISTERED PRODUCT ALREADY

OPTIFLUXSpinning

Technology

OPTIFLUX ENEXASpinning

Technology

PVP

PS

PVP

PSSMM1

As leading expert in hollow fiber membrane technologies weset polysulfone hollow fibers as an industry standard

Transformative membrane surface technology OPTIFLUX ENEXA to increase the quality of life of our patients

Patients to benefit from new industry standardsset by Fresenius Medical Care

Industry has innovated within existing boundaries and compounds. With Endexo, we add a new compound into the spin mass

We improve the membrane surface characteristicsto increase hemocompatibility performance, targeting heparin free HD therapy

DATA ANALYTICSTEAMS

HEALTH CAREPROFESSIONALS

PRODUCTION

MEDICALEXPERTS

RESEARCH &DEVELOPMENT

10/8/2020Workshop | Therapy Innovations Page 6

LEVERAGING DATA POOLS TO CAPTUREBUSINESS GROWTH POTENTIAL

PRODUCTION AND SERVICE DATA

INTELLIGENTPRODUCTIONAND SERIVCES

MACHINE ANDDEVICE DATA

SMART MACHINESAND CLINICALWORKFLOWS

MEDICAL ANDTHERAPY DATA

INDIVIDUALIZEDAND ADAPTEDTHERAPIES

▪ Predictive maintenance

▪ Intelligent productioncapacity planning

▪ Automated testingenvironment

▪ Reduction of dropoutrates in Home patients

▪ Individualized comorbidity management

▪ Transitional care bydata and diagnostics

▪ Automated alarm management

▪ Intelligent Ultra Filtration

AS A FULL VERTICALINTEGRATED COMPANY…

… FME IS IN A UNIQUE POSITION OF LEVERAGING ITS VARIOUS DATA POOLS TO PROVIDE INDIVIDAULIZED AND BEST IN CLASS THERPIES …

Convenience Efficiency Outcome/Efficiency

~ 350,000Dialysis Patients

worldwide

> 50 Mn.Dialysis

treatmentsin 2019

> 4,000Own Dialysis

clinics in around50 countries

10/8/2020Workshop | Therapy Innovations Page 7

REGENERATIVE MEDICINE OFFERSA BROADER PRODUCT SCOPE

REGENERATIVE MEDICINE AS TRANSFORMATIVE RENAL THERAPY

CKD 3 CKD 4 CKD 5 ESRD

Pre-ESRD Treatment/Prevention of ESRD DIALYSIS

TRANSPLANT

REGENERATIVE MEDICINE TO EXPAND INTO CKD AND TRANSPLANT …

… AND AS UNIQUE PLATFORM TO ENTER ADDITIONAL HEALTHCARE SECTORS

▪ Liver disorders

▪ Diabetes

▪ Cardiovasculardiseases

▪ Oncology

▪ …

▪ Diabetes

▪ …